Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Thinks It’s Ready To Withstand Restasis Generics

Executive Summary

Allergan’s Restasis patent cliff is imminent: full-year sales of the dry eye product declined 14% and the firm expects US generic competition by Q2. But Botox growth is steady, Vraylar is poised to add a major indication and other pipeline assets may add growth.

You may also be interested in...



Allergan Acquiesces To Activist Appaloosa With CEO-Chairman Role Split, But Not Yet

Allergan will split the CEO and chairman roles as requested by Appaloosa, but only in the next leadership transition. The activist shareholder fired back with renewed opposition to leaving Brent Saunders in both top jobs.

Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies

Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.

TopiVert Seeks Slot In Dry Eye Disease

The London-based group has begun a Phase IIb/III study evaluating TOP1630 which has a safety and tolerability profile that could prove superior to current treatments such as Allergan's market leader Restasis.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel